Company Filing History:
Years Active: 2018-2019
Title: Innovator Chang-Ill Ban: Pioneering Cancer Treatment Technologies
Introduction
Chang-Ill Ban is a notable inventor based in Pohang-si, South Korea, recognized for his significant contributions to cancer treatment technologies. With two patents to his name, his innovative work focuses on developing targeted therapies that improve outcomes for patients battling cancer.
Latest Patents
Chang-Ill Ban's latest innovations include two groundbreaking patents, both of which are centered around novel aptamer-anticancer drug complexes for chemotherapy. The first patent pertains to an AGTR1 aptamer-anticancer drug complex designed specifically for AGTR1-positive breast cancer cells. This invention utilizes a nucleic acid aptamer that selectively binds to AGTR1, allowing for the precise delivery of anticancer drugs to target and kill overexpressed breast cancer cells.
The second patent involves a HER2 aptamer-anticancer drug complex aimed at HER2-positive breast cancer cells. Similar to the AGTR1 complex, this invention incorporates a nucleic acid aptamer that selectively binds to HER2, ensuring the targeted delivery of the anticancer agent to destroy cancer cells characterized by HER2 overexpression.
Career Highlights
Chang-Ill Ban is associated with the Korea University Research and Business Foundation, where he employs his expertise to foster innovation in medical technology. His pioneering work in the domain of cancer pharmaceuticals has garnered attention, reflecting his commitment to advancing therapeutic strategies in oncology.
Collaborations
In his professional journey, Chang-Ill Ban has worked alongside talented colleagues, including Jae-Hong Seo and Hun-Ho Jo. Their collaborative efforts contribute to a rich environment of innovation and research, pushing the boundaries of what is possible in cancer treatment.
Conclusion
Chang-Ill Ban's work exemplifies the transformative potential of targeted cancer therapies. With his innovative patents, he is making significant strides towards improving chemotherapy's efficacy, ultimately benefiting countless individuals diagnosed with breast cancer. The ongoing research facilitated by the Korea University Research and Business Foundation is a testament to the importance of collaborative efforts in the continuous struggle against cancer.